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Palbociclib 3-weeks-on/1-week-off, combined with hormonal therapy, is approved for hormone receptor positive (HR+)/HER2negative (HER2−) advanced/metastatic breast cancer (MBC). Neutropenia is the most frequent adverse event (AE). We aim to
determine whether an alternative 5-days-on/2-days-off weekly schedule reduces grade 3 and above neutropenia (G3 + ANC)
incidence. In this single-arm phase II trial, patients with HR+/HER2− MBC received palbociclib 125 mg, 5-days-on/2-days-off, plus
letrozole or fulvestrant per physician, on a 28-day cycle (C), as their ﬁrst- or second-line treatment. The primary endpoint was G3 +
ANC in the ﬁrst 29 days (C1). Secondary endpoints included AEs, efﬁcacy, and serum thymidine kinase 1 (sTK1) activity. At datacutoff, ﬁfty-four patients received a median of 13 cycles (range 2.6–43.5). The rate of G3 + ANC was 21.3% (95% CI: 11.2–36.1%)
without G4 in C1, and 40.7% (95% CI: 27.9–54.9%), including 38.9% G3 and 1.8% G4, in all cycles. The clinical beneﬁt rate was 80.4%
(95% CI: 66.5–89.7%). The median progression-free survival (mPFS) (95% CI) was 19.75 (12.11–34.89), 33.5 (17.25–not reached [NR]),
and 11.96 (10.43–NR) months, in the overall, endocrine sensitive or resistant population, respectively. High sTK1 at baseline, C1 day
15 (C1D15), and C2D1 were independently prognostic for shorter PFS (p = 9.91 × 10−4, 0.001, 0.007, respectively). sTK1 decreased
on C1D15 (p = 4.03 × 10−7), indicating target inhibition. Rise in sTK1 predicted progression, with the median lead time of 59.5 (interquartile range: −206.25–0) days. Palbociclib, 5-days-on/2-days-off weekly, met its primary endpoint with reduced G3 + ANC,
without compromising efﬁcacy. sTK1 is prognostic and shows promise in monitoring the palbociclib response. ClinicalTrials.gov#:
NCT3007979.
npj Breast Cancer (2022)8:35 ; https://doi.org/10.1038/s41523-022-00399-w

INTRODUCTION
Hormone receptor positive (HR+) and human epidermal growth
factor receptor 2 negative (HER2−) breast cancer accounts for
~70% of breast cancer diagnoses and is a leading cause of cancer
death in women1,2. The discovery of cyclin D/cyclin-dependent
kinase 4/6 (CDK4/6) as a key downstream target of estrogen
receptor (ER) and endocrine resistance mechanisms has led to the
development of CDK4/6 inhibitors for the treatment of
HR+/HER2− breast cancer3,4. CDK4/6 inhibitors, including palbociclib, ribociclib, and abemaciclib, have gained FDA approval
based on the signiﬁcant improvement in progression-free survival
(PFS) when added to endocrine therapy in patients with advanced
disease as front-line therapy5–11 or following disease progression
on prior endocrine therapy12–14. Overall survival (OS) beneﬁt has
also been observed in several studies15–17. These agents have now
become the standard of care in combination with an endocrine
therapy partner for HR+/HER2− metastatic breast cancer (MBC).
However, treatment-related neutropenia is a common adverse
event (AE), leading to dose interruption, reduction, and at times
discontinuation. Palbociclib (Ibrance, Pﬁzer) is the ﬁrst CDK4/6
inhibitor approved in combination with an aromatase inhibitor as
ﬁrst-line therapy and with fulvestrant following prior hormonal
therapy based on results from PALOMA trials5,9,10,13. Neutropenia
was the most frequent high grade (G) AE related to palbociclib in
PALOMA-2 (79.5% all grades, 56.1% G3, 10.4% G4) and PALOMA-3

(78.8% all grades, 53.3% G3, 8.7% G4)9,13. Febrile neutropenia
occurred in 1.8%, while dose reduction occurred in over a third of
patients who received palbociclib across PALOMA-2 and PALOMA39,13,18. In addition, with the half-life of palbociclib being ~27 h,
recovery of Rb phosphorylation and cell proliferation during the
off-treatment week is a concern. In a longitudinal biomarker study
of palbociclib plus letrozole, recovery of tissue Rb phosphorylation
and Ki67 levels to baseline was observed on day 3 and day 4–5
during the off week, respectively19. We, therefore, proposed a 5days-on/2-days-off weekly schedule to allow bone marrow
recovery during the 2 off days to avoid the week-long break.
We hypothesize that this alternative schedule is more tolerable
with less frequent high-grade (G3+) neutropenia and dose
interruptions/reductions compared to the historical data with
the 3-weeks-on/1-week-off schedule. Based on our previous study
supporting serum thymidine kinase 1 (sTK1), an E2F-dependent
enzyme critical for DNA synthesis, as a pharmacodynamic
indicator of CDK4/6 inhibition20, we assessed sTK1 dynamics for
target inhibition, and examined its potential prognostic value and
utility in disease monitoring in this study.
RESULTS
Between 12 July 2017 and 14 Feb 2020, 54 patients with
HR+/HER2− MBC were enrolled to receive palbociclib plus
letrozole (n = 41) or fulvestrant (n = 13) per physician’s choice
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Table 1.

Clinical Characteristics (n = 54).

Characteristics

N (%)

Age, years
Median (range)

61 (34–87)

Race
White
African American
ECOG PS
0

45 (83%)
9 (17%)
29 (54%)

1

21 (39%)

2

4 (7%)

Menopausal status
Premenopausal

8 (15%)

Postmenopausal

46 (85%)

Endocrine drug partner
Letrozole
Fulvestrant

41 (76%)
13 (24%)

Visceral metastases
1234567890():,;

Yes

28 (52%)

Prior therapy
Neo/adjuvant chemotherapy

22 (41%)

Neo/adjuvant endocrine therapy

29 (54%)

Metastatic chemotherapy
Metastatic endocrine therapy
Setting of trial therapy, endocrine sensitivitya

0 (0%)
4 (7%)

1st line, de novo stage IV, endocrine sensitive

20 (37%)

1st line, recurrent stage IV, endocrine sensitive

12 (22%)

1st line, primary endocrine resistance
1st line, secondary endocrine resistance

1 (2%)
17 (31%)

2nd line, primary endocrine resistance

1 (2%)

2nd line, secondary endocrine resistance

3 (6%)

a

Per ESMO guideline (Cardoso et al.21), deﬁned as the following:
Endocrine sensitive: relapse at least 12 months following completing of
adjuvant endocrine therapy or with de novo MBC.
Primary endocrine resistance: relapse while on the ﬁrst 2 years of adjuvant
endocrine therapy, or PD within the ﬁrst 6 months of 1st line endocrine
therapy for advanced breast cancer, while on endocrine therapy
Secondary endocrine resistance: relapse while on adjuvant endocrine
therapy but after the ﬁrst 2 years, or relapse within 12 months of
completing adjuvant endocrine therapy, or PD ≥ 6 months after initiating
endocrine therapy for advanced breast cancer, while on endocrine therapy.

(Table 1). Premenopausal women (n = 8) also received goserelin.
Twenty-two (41%) patients had primary or secondary endocrine
resistance by ESMO guideline (footnote of Table 1)21. As of the
data cutoff date of 15 Dec 2020, at a median follow-up of 27.04
(95% CI: 23.89–41.82) months, treatment is ongoing for 19 (35%)
patients. A majority (17/54, 31%) of patients went off study due to
progression (Supplementary Fig. 1).
Forty-seven patients were evaluable for the primary endpoint of
G3 + ANC during C1D1-29 (Supplementary Figure 1). Ten (21.3%,
95% CI: 11.2–36.1%) had G3 ANC, without G4 AE, in C1D1-29
(Table 2). As a pooled analysis of PALOMA trials published recently
indicted a G3 + ANC rate of ~45%18, we performed a post hoc
power calculation that tested the observed 21.3% rate against the
null hypothesis >44.7%. With N = 47, the post hoc power is
94.04% based on a 1-sided Binomial exact test at 5% alpha level.
Twenty-two of 54 (40.7%; 95% CI: 27.9–54.9%) had G3 (n = 21)
or G4 (n = 1) ANC in all cycles. Non-hematologic toxicities were
uncommon and mostly G1/G2 (Table 2). There was no neutropenic
npj Breast Cancer (2022) 35

fever. Among the 51 patients who completed at least 1 cycle of
therapy, the median dose intensity was 97% (range 54–100%)
with a median of 14 (2–44) months of treatments (Table 3).
Palbociclib was dose reduced to 100 mg in 12 (24%) patients due
to G3 ANC (n = 8), thrombocytopenia (n = 1), physician decision
(n = 1), or G3 aspartate aminotransferase/alanine aminotransferase (AST/ALT) (n = 2), then further reduced to 75 mg in 8 of these
12 patients due to G3 ANC (n = 6), ALT (n = 1), thrombocytopenia
(n = 1). Three (68%) of these 51 patients discontinued due to AE,
including 2 due to G3 ANC, and 1 death (G5) due to subdural
hematoma, with platelet count of 59 K. There were no other G5
events.
Clinical beneﬁt at 24 weeks was observed in 41 of 51 evaluable
patients, with a CBR of 80.4% (95% CI: 66.5–89.7%), including 2 CR,
14 PR, and 25 SD ≥ 24 weeks (Supplementary Table 1). ORR was
53.3% (95% CI: 34.6–71.2%) in the 30 patients with measurable
disease (n = 29) or with non-measurable disease but experienced
CR (n = 1). The mPFS was 19.75 months (95% CI: 12.11–34.89)
overall (Fig. 1a), 11.96 (95% CI: 10.43~NR) and 33.5 months (95%
CI: 17.25~NR) in the endocrine resistant, or sensitive population,
respectively (Fig. 1b).
To assess treatment-induced pharmacodynamics effect, we
analyzed sTK1 activity on serial blood collected at baseline (n =
51), C1D15 (n = 46), C2D1 (n = 45), C4D1 with 1st tumor imaging
(n = 33), and at progression for 24 patients who had RECIST
progression (n = 17) or by investigator decision (n = 7). All
available samples were tested. 16 of 17 patients with RECIST
progression had serial sTK1 assayed every ~3 cycles until
progression. The median (interquartile range) sTK1 was 97.87
(42.4–490.3) Du/L at baseline, reduced to <20 (<20~<20) Du/L at
C1D15, remained low at <20 (<20~54.1) Du/L at C2D1 and <20
(<20~30.5) Du/L at C4D1 (excluding patients progressed at C4D1),
and increased to 162.2 (70.7~793.1) Du/L at disease progression
(Fig. 2a, Supplementary Fig. 2, Supplementary Table 2). Comparison of sTK1 levels between selected time points are shown in
Supplementary Table 3. sTK1 was undetectable (<20 Du/L) in
13.7% (7/51) at baseline, 78.2% (36/46) at C1D15, 63.6% (28/44) at
C2D1, and 8.3% (2/24) at progression. All patients with high sTK1
at C1D15 (≥20 Du/L) had high sTK1 at baseline (>200 Du/L,
predeﬁned cut point for high baseline sTK1). Among the 24
patients who progressed with sTK1 available, an sTK1 increase
from the prior time point was detected at the time of progression
in nine patients, and at an earlier time point in 13 patients
(Supplementary Table 4), with the median (inter-quartile range)
lead time of 59.5 (−206.25–0) days, Wilcoxon signed rank test p =
0.0017 (Fig. 2a, c and Supplementary Table 4).
We then assessed the prognostic signiﬁcance of baseline and
early on-treatment sTK1. There was no association between levels
of sTK1 either at baseline or C1D15 with the presence of visceral
metastasis or endocrine sensitivity deﬁned by ESMO criteria
(Supplementary Tables 5, 6). However, sTK1 at both BL and C1D15
time points were signiﬁcantly correlated with clinical beneﬁt
versus not (Supplementary Tables 5, 6). Baseline sTK1 was higher
in patients with PD as the best response (Supplementary Fig. 3a;
Supplementary Table 5). Progression within 6 months (not
achieving clinical beneﬁt) was negatively correlated with high
sTK1 at baseline (p = 0.000419) and C1D15 (p = 8.4 × 10−5)
(Supplementary Fig. 3b, c). High sTK1 at baseline (>200 Du/L),
C1D15 (>20 Du/L) or C2D1 (>20 Du/L) predicted progression
within 3 (or 6) months with a speciﬁcity of 71.1% (78.0%), 82.5%
(89.2%), 65.8% (73.5%), and sensitivity of 50% (70%), 50% (66.7%),
50% (70%), negative predictive value (NPV) of 91.4% (91.4%),
91.6% (91.7%), and 89.3% (89.3%), and positive predictive value
(PPV) of 18.8% (43.8%), 30% (60%), and 18.8% (43.8%), respectively
(Supplementary Table 7). High baseline sTK1 (>200 Du/L) was
negatively correlated with PFS (p = 9.91 × 10−4), as was incomplete suppression of sTK1 (≥20 Du/L) at an early on-treatment time
point at C1D15 (p = 0.001) or C2D1 (p = 0.007) (Fig. 3). The mPFS
Published in partnership with the Breast Cancer Research Foundation
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Table 2.

Adverse events.

AE

G1

G2

G3

G4

Total

13 (28%)

C1 D1-29 (n = 47)
Non-hematologic AE
Fatigue

13 (27.7%)

0

0

0

Hot ﬂashes

7 (14.9%)

0

0

0

7 (15%)

Nausea

6 (12.8%)

0

0

7 (15%)

Alopecia
Dizziness

5 (10.6%)
1 (2.1%)

0
0

5 (11%)
2 (4%)

1 (2.1%)
0
0

0
1 (2.1%)

Laboratory investigation
Leukopenia

13 (27.6%)

22 (46.8%)

7 (14.9%)

0

42 (89%)

Neutropenia

6 (12.8%)

18 (38.3%)

10 (21.3%)

0

34 (72%)

18 (38.3%)

5 (10.6%)

0

23 (49%)

0

16 (34%)

Anemia

0

Lymphopenia

6 (12.8%)

8 (17%)

2 (4.3%)

Thrombocytopenia

5 (10.6%)

1 (2.1%)

0

0

6 (13%)

Fatigue

20 (37.0%)

4 (7.4%)

0

0

24 (44.4%)

Nausea

19 (35.2%)

3 (5.6%)

0

0

22 (40.7%)

Alopecia

19 (35.2%)

0

0

0

19 (35.2%)

Dizziness

4 (7.4%)

0

1 (1.9%)

0

0

1 (1.9%)

0

1 (1.9%)

0

1 (1.9%)

0

2 (3.8%)
51 (94.5%)

All cycles (n = 54)
Non-hematologic AE

Sepsis
Weight loss
Laboratory investigation
Leukopenia
Neutropenia
Anemia
Lymphopenia
Thrombocytopenia
ALT elevated
AST elevated

0
1 (1.9%)

5 (9%)

7 (13.0%)

21 (38.9%)

23 (42.6%)

0

2 (3.7%)

24 (44.4%)

21 (38.9%)

1 (1.9%)

48 (88.9%)

27 (50.0%)

11 (20.4%)

4 (7.4%)

0

42 (77.8%)

6 (11.1%)

18 (33.3%)

11 (20.4%)

0
0

35 (64.8%)
18 (33.3%)

17 (31.5%)
3 (5.6%)

0
0

1 (1.9%)a
2 (3.7%)

0

5 (9%)

4 (7.4%)

0

1 (1.9%)

0

5 (9%)

All grade 3 AEs, AEs > 10% incidence in the ﬁrst 29 days, and AEs > 15% incidence all cycles are included.
a
Patient died from subdural hematoma (G5).

(95% CI) for patients with high (≥20 Du/L) sTK1 (n = 10) or low
sTK1 (n = 36) at C1D15 was 4.25 (3.14~NA) and 20.93 (18~NA)
months, respectively (HR = 3.9, p = 0.001) (Fig. 3). sTK1 at BL,
C1D15, and C2D1 remained an independent predictor of PFS in
the multivariate analysis that included age, endocrine sensitivity,
and sites of metastases (Supplementary Table 8).
DISCUSSION
CDK 4/6 inhibitors represent a major advance in the treatment of
HR+/HER2− MBC. However, a one-week break following 3 weeks
of administration is required for both palbociclib and ribociclib
due to treatment-induced neutropenia22,23. To improve the
tolerability and to avoid the 1-week break, which has been shown
to led to the recovery of target inhibition in previous studies19, we
tested palbociclib at 125 mg in a 5-days-on/2-days-off weekly
schedule, in combination of letrozole or fulvestrant per physician’s
choice as 1st line or 2nd line systemic therapy in this phase II trial
in patients with HR+/HER2− MBC. In this trial, we observed G3 +
ANC rate of 21.3% (95% CI: 11.2%–36.1%, without G4) in D1-29,
and 40.7% (95% CI: 27.9%–54.9%) (1.9% G4) in all cycles with a
median dose intensity of 97% (range 54–100%) in a median of
14 months of drug therapy. Dose reduction occurred in 24% of
patients, including 6% who discontinued therapy. The trial met
the primary endpoint of reduced incidence of G3 + ANC and
Published in partnership with the Breast Cancer Research Foundation

improved tolerability of palbociclib administered in a 5-days-on/2days-off weekly schedule compared to historical data from
palbociclib trials9,13,18.
To assess target inhibition, we examined serial sTK1 activity as a
surrogate pharmacodynamics marker in this trial, and demonstrated a signiﬁcant reduction of sTK1 to an undetectable level in
78.2% of patients at C1D15. This result mirrors the impressive
reduction in sTK1 observed 2 weeks after initiation of palbociclib
in our prior study of patients with early stage HR+/HER2− breast
cancer receiving neoadjuvant palbociclib and anastrozole20. The
signiﬁcant reduction of sTK1 at C1D15 and C2D1 indicates that the
5-days-on/2-days-off schedule achieved effective target inhibition
and provides reassurance with the 2-day break each week.
This alternative schedule offers an advantage in avoiding the
1-week break with a 3-weeks-on/1-week-off schedule, which
potentially compromises the efﬁcacy of CDK4/6 inhibitors because
of their short terminal half-life (~26 h for palbociclib23; 32.6 h for
ribociclib22). In a biomarker study that assessed the longitudinal
effect of palbociclib following a single dose or 3-week administration on Ki67 and pRb expression in skin biopsies and sTK1 in
blood samples collected from 26 patients with HR+/HER2− MBC,
recovery of pRb, Ki67, and sTK1 was observed during the offtreatment week, back to baseline on day 2–3 for pRb, day 3–4 for
Ki67 and sTK119. The rebound of sTK1 at the end of C1 therapy
with the 3-weeks-on/1-week-off schedule was also demonstrated
npj Breast Cancer (2022) 35
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in the recent report by Malorni et al.24, in patients who received
palbociclib plus fulvestrant. In contrast, the alternative 5-days-on/
2-days-off schedule led to consistently profound reductions in
sTK1 on C1D15 and C2D1, following the 2-day break from the
previous week. In this trial, we observed a respectable CBR of
80.4% (95% CI: 66.5%–89.7%) and mPFS (95% CI) of 19.75
(12.11–34.89) months in a patient population treated in the 1st
or 2nd line metastatic setting. The mPFS of 33.5 (17.25~not
reached [NR]) in the endocrine sensitive population was
numerically comparable to the mPFS of 27.6 months observed
in the PALOMA-25, with the caveat of cross-trial comparison.
Similarly, the mPFS of 11.96 (10.43~NR) months observed in the
endocrine-resistant population was comparable to that reported
in PALOMA-3 (mPFS 11 months in the updated analysis)25.
In addition, our study demonstrated the potential utility of sTK1
activity at baseline and on-treatment as a prognostic marker and
in monitoring disease status for patients with MBC receiving a
CDK4/6 inhibitor. High sTK1 at baseline or early on-treatment time
point (C1D15 or C2D1), especially at C1D15, had high degrees of
accuracy in predicting progression within 6 months (84% accuracy
for C1D15). In addition, we demonstrated that a rise in sTK1
predicted subsequent clinical/RECIST progression.
Our data are consistent with previous studies demonstrating
that a higher baseline sTK1 is associated with a shorter time to
progression in patients with advanced HR+/HER2− breast cancer
receiving endocrine therapy and a rise in sTK1 on-therapy from
Table 3.

Exposure to palbociclib.

Exposure to palbociclib (n = 51)
Treatment duration, month
Median (range)
Relative dose intensitya
Median (range)
Mean (Standard deviation)

14 (2–44)
97% (54%–100%)
90% (14%)

Dose modiﬁcations (any cause)
Dose reductions, N (%)
≥1 dose reduction

12 (24%)

1 dose reduction

4 (8%)

2 dose-level reduction

8 (16%)

Discontinuation due to AE
N (%)

3 (6%)

Dose Interruptions due to AE
N (%)

33 (65%)

Relative dose intensity = [(actual dose)/ (intended dose)]*100%.

a

Fig. 1

baseline was associated with treatment resistance26–29. Few
studies have evaluated sTK1 activity in patients receiving standard
dosing palbociclib in combination with endocrine therapy.
McCartney et al analyzed serial plasma TK1 activity at baseline
(T0), after 1 cycle (T1), and at progression (T2) in 46 patients with
HR + MBC treated with palbociclib within the TREnd trial30. The
median TK1 activity was 75 Du/L at T0, decreased to 35 Du/L at T1,
and increased to 251 Du/L at progression30. Patients with
increasing TK1 at T1 correlated with a worse outcome than those
with decreased/stable TK1 (n = 33; mPFS 3.0 vs 9.0 months; p =
0002), similar to our study30. Although TK1 above the median at T2
was associated with worse outcomes on post-study therapy,
baseline TK1 was not prognostic30. In addition, in vitro studies
demonstrated that TK1 reduction occurred in palbociclib sensitive
but not resistant cells30. Cabel et al.31 reported a study that
assessed the plasma TK1 activity at baseline and a 4-week time
point in 103 patients with ER+/HER2− MBC treated with
palbociclib and endocrine therapy, which demonstrated that
baseline TK1 activity (using median value as cutoff) was an
independent prognostic factor for both PFS and OS, but adding
TK1 activity at 4 weeks did not further increase survival prediction.
More recently, Malorni et al. assessed TK1 at pre-treatment, C1D15,
and D28 in patients with endocrine-resistant luminal MBC
receiving palbociclib and fulvestrant. In this study, TK1 was
signiﬁcantly suppressed on C1D15, with 90/108 (83%) patients to
<20 Du/L, similar to our observation with the 5-days-on/2-days-off
schedule. However, on D28, a TK1 rebound was observed in most
patients in the Malorni study, with TK1 < 20 Du/L in only 29%
patients, while 28 of 44 (63.6%) had TK1 < 20 Du/L on C2D1 in our
study. Similar to our study, at each time point, higher TK1 was
signiﬁcantly and consistently associated with shorter PFS, with
C1D15 being most prognostic. However, none of the prior studies
assessed longitudinal TK1 activity assessment until progression.
Our study is the ﬁrst to show that increases in TK1 occur earlier
than clinical progression, indicating detection of subclinical
progression.
Our study is limited by the small sample size and the nonrandomized single-arm trial design. The data regarding sTK1, at BL
and early on-treatment time points, in predicting response on
CDK4/6 inhibitors is intriguing as there are no predictive
biomarkers currently available for CDK4/6 inhibitors. Future
prospective trials are warranted to conﬁrm our results on the
safety and efﬁcacy of the 5-days-on/2-days-off weekly schedule
and to validate the clinical utility of sTK1 in guiding the
management of patients with HR + /HER2- MBC.
In conclusion, this single-arm phase II trial of palbociclib
administered at an alternative 5-days-on/2-days-off weekly schedule,
in combination with either letrozole or fulvestrant, met the predeﬁned
primary endpoint in reducing the incidence of high-grade neutropenia, without compromising efﬁcacy. While randomized trials are

Progression-free survival (PFS) of all treated patients. a the overall population, and b by endocrine sensitivity.
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Fig. 2 Serum TK1 activity over time. a Box plot of log (sTK1 Du/L) along the 5-time points indicated. b Time to progression by TK1 increase
from the previous time point (sTK1 PD) or by RECIST/investigator decision (Clinical PD). c The lead time from TK1 progression to clinical/RECIST
progression. BL baseline, C1D15 cycle 1 day 15, C2D1 cycle 2 day 1, Progression PFS events that included RECIST progression (n = 17) and
investigator decision (n = 7). The center horizontal line of the box plot indicates the median, while the box limits indicate the upper and lower
quartiles. The box-plot whiskers show a 1.5× interquartile range. Those points outside the whisker line are indicated as outliers. *p < 0.05, ***p <
0.001.

Fig. 3 PFS by sTK1 and time points of baseline (BL), C1D15, C2D1, C4D1. sTK1 cutoff for high versus low is 200 at BL (a) and 20 at time
points C1D15 (b) and C2D1 (c). Shown in legends are even/n (number of events/total samples), median PFS, 95% CI by group, log rank test P,
and HR (hazard ratio: high sTK1 vs. low sTK1) with 95% CI. The number of patients at risk is indicated at the bottom of each plot.

needed to conﬁrm this ﬁnding, this alternative schedule provides an
option for patients having difﬁculty tolerating the standard 3-weekson/1-week-off schedule and to potentially avoid drug discontinuation
due to neutropenia. Our data demonstrate sTK1 activity a promising
biomarker of prognosis and disease monitoring in patients receiving
CDK4/6 inhibitors.
METHODS
Study design and participants
A single-arm phase II study was conducted at Washington University
School of Medicine, St. Louis, MO, and University of Nebraska Medical
Center, Omaha, NE. Eligible patients were ≥18 years old, Eastern
Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2 with HR
+ /HER2− on the most recent biopsy, MBC with measurable or evaluable
disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. HR+
was deﬁned as ER+ and/or progesterone receptor positive (PR+) ≥ 1% of
tumor cells. HER2- was deﬁned per the 2013 ASCO/CAP guideline (2018
updated guideline was used for patients enrolled after May 30, 2018). Zero
or one prior systemic therapies (chemotherapy or endocrine therapy) for
MBC was allowed. Prior CDK4/6 inhibitor was not allowed. Laboratory
Published in partnership with the Breast Cancer Research Foundation

requirements include absolute neutrophil count (ANC) ≥ 1500/mcl, platelets ≥100,000/mcl, total bilirubin ≤ the institutional upper limit of normal
(IULN) or total bilirubin ≤3.0× IULN with direct bilirubin within the normal
range in patients with Gilbert’s syndrome, AST (SGOT)/ALT (SGPT) ≤ 1.5×
IULN (up to 5× IULN in patients with liver disease, Creatinine ≤ IULN or
creatinine clearance ≥60 mL/min/1.73 m2 as determined by CockcroftGault Equation for patients with creatinine > IULN. A washout of ≥3 weeks
from prior chemotherapy or targeted therapy that induces myelosuppression and recovery of treatment-related AEs (except alopecia) to ≤G1 was
required. All patients provided written informed consent. The study was
approved by institutional review boards at the Washington University in St.
Louis School of Medicine and the University of Nebraska Medical Center.
The Clinicaltrials.gov# is NCT03007979.

Treatment and procedures
Patients received palbociclib 125 mg daily, on a 5-days-on/2-days-off
weekly schedule, and letrozole or fulvestrant per physician’s choice, on a
28-day cycle (C). Goserelin was administered in premenopausal patients.
Complete blood count and chemistry panel were done at baseline, C1 and
C2 Day (D) 15, and D1 of each cycle on C2+. Dose modiﬁcations were
assessed according to guidelines in the FDA packaging insert for
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palbociclib, except for the use of the 5-days-on/2-days-off schedule. AEs
were accessed by NCI Common Terminology Criteria for Adverse Events
(CTCAE) 4.0. Patients underwent tumor evaluation by RECIST v1.1 every 3
cycles. Research blood was collected at baseline, C1D15, C2D1, and C4D1,
then on D1 of every 3 cycles (with tumor imaging) until disease
progression. sTK1 was analyzed retrospectively using the DiviTum® assay
(Biovica International, Uppsala, Sweden)20,32 for all patients with available
samples at baseline, C1D15, C2D1, and C4D1, as well as every 3 cycles up
to progression in those who progressed by the time of data cutoff. TK1
activity was determined using a reﬁned ELISA-based method (DiviTum®)
according to the manufacturer’s instruction (www.biovica.com) and was
performed at the Biovica laboratory in Uppsala, Sweden, with laboratory
investigators blinded to patient data.

Outcomes
The primary endpoint was the rate of G3 + ANC between C1D1 and C2D1
(C1D1-29). The sample size of 47 provided 90% power, based on a onesample binomial exact test at alpha = 5%, to test the one-sided null
hypothesis of G3 + ANC rate >62%, an estimate based on incidences from
prior phase III trials of palbociclib10,13 and that neutropenia occur early in
the course of therapy33, versus the alternative of <40%. If G3 + ANC was
observed in ≤23 patients, the 5-days-on/2-days-off schedule will be
deemed as having less neutropenia than the standard schedule. As a
subsequent pooled analysis of safety data from three randomized trials
(PALOMA-1, 2 and 3) indicates, the rate of G3 + neutropenia in C1 in the
palbociclib arm was 44.7%18, lower than what we originally expected. A
post hoc power calculation was performed on testing against the null
hypothesis H0: G3 + neutropenia rate >44.7% versus the observed 21.3%
(10 out of 47, including the occurrences on C2D1 beyond C1 D1 to D28) in
this trial. With N = 47, the post hoc power is 94.04% based on a one-sided
Binomial exact test at 5% alpha level. Secondary endpoints include the rate
of G3 + ANC in all cycles, palbociclib dose intensity/reduction/interruption/
discontinuation, AEs, PFS for the overall population and for the endocrine
sensitive or resistant population as deﬁned by ESMO guideline21, objective
response rate (ORR: CR + PR (complete and partial responses)) and clinical
beneﬁt rate (CBR: CR + PR + Stable disease (SD) ≥ 24 weeks by RECIST 1.1).
Other endpoints include sTK1 at baseline, C1D15, C2D1, and progression,
in relation to PFS and CBR, as well as, the lead time from sTK1 rise during
therapy to disease progression deﬁned by RECIST.

Statistical analysis
Patient characteristics and AEs were summarized by descriptive statistics.
AE rate, ORR, and CBR were estimated accompanied with 95% conﬁdence
interval (CI). PFS was deﬁned from the date on treatment to off-study date
(due to radiographic progression, clinical deterioration, investigator
decision, AE) or date of death and to the date of the last imaging scan
demonstrating no progression if patients had no events. Survival
endpoints were analyzed by Kaplan–Meier (KM) method and survival
difference was compared between patient groups of interests by log-rank
test. Cox proportional hazard model was applied to estimate the hazard
ratio (HR) with 95% CI. sTK1 ≤ 20 Du/L was deemed undetectable and was
replaced with 19 Du/L for analysis. sTK1 was compared between time
points by Wilcoxon signed-rank test with p values corrected by the
Benjamini-Hochberg method to control false discovery rate (FDR). Baseline
and on-treatment sTK1 was compared between patients who had the
clinical beneﬁt (CB) or progressive disease (PD) versus not by the Wilcoxon
rank-sum test. sTK1 was dichotomized to high versus low by a pre-deﬁned
cutoff of 200 Du/L at baseline28,29 and 20 Du/L at on-treatment time
points24 and was then analyzed in relation to PFS by KM method and logrank test. Diagnostic test operating characteristics including speciﬁcity,
sensitivity, negative and PPV of the dichotomized sTK1 at different time
points were derived for the binary outcomes (CB vs non-CB; PD vs non-PD).

Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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